TY  - JOUR
AU  - Quintela Fandino, Miguel Angel
AU  - Apala, Juan V
AU  - Malon, Diego
AU  - Mouron, Silvana Andrea
AU  - Hornedo, Javier
AU  - Gonzalez-Cortijo, Lucia
AU  - Colomer, Ramon
AU  - Guerra, Juan
PY  - 2019
DO  - 10.1186/s13058-019-1152-x
SN  - 1465-542X
UR  - http://hdl.handle.net/20.500.12105/7806
AB  - BACKGROUND: The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification. However, no pharmacodynamic studies have addressed the effects of this combined target modulation. We...
LA  - eng
PB  - BioMed Central (BMC)
KW  - FGF23
KW  - FGFR1
KW  - Letrozole
KW  - Nintedanib
KW  - Pharmacodynamics
KW  - Phase 0 clinical trial
KW  - Phase I clinical trial
TI  - Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
TY  - journal article
ER  -